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Abstract
Background: This study aims to contribute to the knowledge of the influence of comorbidity in
OA. The objectives of the study were (i) to describe the prevalence of comorbidity and (ii) to
describe the relationship between comorbidity (morbidity count, severity and the presence of
specific diseases) and limitations in activities and pain in elderly patients with knee or hip OA using
a comprehensive inventory of comorbidity.
Methods: A cross-sectional cohort study was conducted, in which 288 elderly patients with hip
or knee osteoarthritis were included. Apart from demographic and clinical data, information about
comorbidity, limitations in activities (WOMAC, SF-36 and timed walking test) and pain (VAS) was
collected by questionnaires and tests. Statistical analyses included descriptive statistics, multivariate
regression techniques, t-tests and one-way ANOVA.
Results: Almost all patients suffered from at least one comorbid disease, with cardiac diseases,
diseases of eye, ear, nose, throat and larynx, other urogenital diseases and endocrine/metabolic
diseases being most prevalent. Morbidity count and severity index were associated with more
limitations in activities and with more pain. The presence of most of the moderate or severe
diseases and obesity was associated with limitations in activities or with pain.
Conclusion:  The results of this study emphasize the importance of comorbidity in the
rehabilitation of elderly patients with osteoarthritis of the hip or knee. Clinical practitioners should
be aware of the relationship of comorbidity with functional problems in OA patients.
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Background
Elderly patients with osteoarthritis (OA) frequently suffer
comorbidity. Comorbidity refers to the coexistence of
other conditions with a defined index disease [1,2]. OA is
one of the diseases with the highest rate of comorbidity
[1,3-6]. Patients with OA have a significantly higher risk of
developing comorbidity than non-OA patients [4,7].
Studies focussing on comorbidity in OA showed that
chronic conditions, such as hypertension, cardiovascular
diseases, obesity, respiratory diseases and diabetes can be
found alongside OA [1,3-5,8].
There is evidence that comorbidity is related to disability
in general populations [9-13]. Studies on the relationship
between comorbidity and disability in OA showed similar
results [3,5,8,14]. Morbidity count (the number of dis-
eases) was associated with limitations in activities in end
stage hip osteoarthritis [5]. In a population recruited from
general practice, an association between morbidity count
and pain or quality of life in patients with hand, knee or
hip OA was established [3,8]. Likewise, an effect of
comorbidity on quality of life and limitations in activities
was found in patients that were placed on a waiting list for
total hip replacement [14]. Also, longitudinal studies pro-
vided evidence for a relationship between comorbidity
and limitations in activities [15,16]. Obesity, an impor-
tant health hazard, can be regarded as a comorbidity and
has been found to be associated with limitations in activ-
ities, body functions and quality of life in OA [11,17,18].
Apart from the studies on obesity, none of the former
studies assessed the relationship between the presence of
specific diseases and limitations in activities. This is sur-
prising since some diseases, in combination with OA,
might be associated with limitations in activities, whereas
others might not [19]. The majority of the studies on
comorbidity focussed on morbidity count. Comorbidity
lists in these studies varied with regard to the number of
diseases included in the list and the type of diseases that
were studied. Studies often only focussed on the most
prevalent diseases. Furthermore, in none of the studies
severity of the comorbid conditions was taken into
account. A comorbidity measure that includes all possible
disease categories and severity is the Cumulative Illness
Rating Scale (CIRS) [20]. Thus, the CIRS allows a more in
depth analysis of comorbidity in OA than is available in
previous studies.
The objectives of the study were (i) to describe the preva-
lence of comorbidity and (ii) to describe the relationship
between comorbidity (morbidity count, severity and the
presence of specific diseases) and limitations in activities
and pain in elderly patients with knee or hip OA using a
comprehensive inventory of comorbidity.
Methods
Design
A cross-sectional study was conducted in 288 patients
with knee or hip OA. The study was approved by the Med-
ical Ethical Committee of the VU University Medical Cen-
tre, Amsterdam, the Netherlands.
Study population
Patients were recruited from three rehabilitation centres
and two hospitals (departments of Orthopaedics, Rheu-
matology or Rehabilitation). The present study is part of a
larger research program on rehabilitation of elderly
patients with OA of the hip or knee. For this reason, we
focussed on rehabilitation centres and hospitals in recruit-
ing patients. Inclusion criteria were: (a) diagnosis of hip
or knee OA by medical specialist according to radiological
criteria (only if X-rays were available) or clinical criteria of
the American College of Rheumatology; (b) 50 years of
age or older; (c) referral to hospital or rehabilitation cen-
tre less than a year before inclusion; (d) at least moderate
functional problems (Lequesne algofunctional index
score ≥ 5) [21] and (e) informed consent. Exclusion crite-
ria were: (a) 85 years of age or older; (b) insufficient
understanding of the Dutch language and (c) expected
death within one year after inclusion due to fatal illness.
Initially, 775 patients with osteoarthritis of the hip or
knee that visited the department in the year prior to inclu-
sion were contacted by mail and were asked to participate
in the study. Of those patients that volunteered (n = 364),
288 were included. 76 patients were excluded because
they did not meet the inclusion criteria. Reasons of exclu-
sion were age (n = 2), language (n = 4), less than moderate
functional problems (n = 48) and referral longer than one
year before inclusion (n = 22). Analyses showed that there
were no differences between the group of patients that
were initially contacted (N = 775) and the patients that
were included in the study (N = 288) with regard to age
and gender. Some differences were found in the location
of OA. Compared to our study population, patients that
were initially contacted suffered less frequently from both
hip and knee OA (6.2%) and more frequently from knee
OA (59.5%) and hip OA (34.3%).
Measurements
Measurements were carried out by means of tests, ques-
tionnaires and interviews. Assessments were performed
on test locations by the researcher or the research assist-
ant.
Demographic and clinical data
Demographic and clinical data were collected for each
patient including age, gender, height, weight, location of
OA, duration of complaints, other joint complaints, level
of education and marital state. If available, X-rays of theBMC Musculoskeletal Disorders 2008, 9:95 http://www.biomedcentral.com/1471-2474/9/95
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hip and knee that were recorded in the year prior to inclu-
sion were scored on joint space width and osteophytes,
following a standardized procedure [22,23]. A 0–3 scale
was used for rating the radiographs: 0 = normal; 1 = mild
or 1–33% abnormal; 2 = moderate or 34–66% abnormal;
3 = severe or 67–100% abnormal. Data on radiological
impairments were summarized into one score for the hip
and one score for the knee. This summary score was deter-
mined by the highest score on either joint space width or
osteophytes.
Limitations in activities and pain
Limitations in activities were measured using the physical
functioning subscale of the MOS 36 item Short Form
Health Survey (SF-36) [24,25], a 10 meter timed walking
test [26] and the physical functioning subscale of the
Western Ontario and McMaster Universities Osteoarthri-
tis Index (WOMAC) [27,28]. Pain was rated at the time of
assessment on a Visual Analogue Scale (VAS) (range
0–10). A higher score on SF-36 and the WOMAC reflects
fewer limitations in activities, whereas a higher score on
the VAS means more pain.
Comorbidity
Information about comorbidity was gathered in an inter-
view with the patient using the Cumulative Illness Rating
Scale (CIRS) [20,29,30]. The CIRS consists of 13 domains
related to different body systems. Examples of diseases
included in the different categories of the CIRS were given
in the description of the instrument. Scoring on the differ-
ent domains is weighted by the severity of the comorbid
condition. Severity scores range from 0 (none) to 4
(extremely severe). More details about the CIRS are pre-
sented in Figure 1. Because all patients suffered from OA
and this disease is used as the index disease, CIRS category
#10 (muscle, bone and skin diseases) was excluded from
the analyses. Indices of comorbidity that were derived
from the CIRS were the presence (0/1) of the different dis-
ease categories, morbidity count and the severity index
(sum score on the CIRS divided by morbidity count).
With regard to morbidity count two calculations were
made: (i) the number of diseases on which the patients
scored 1 or higher and (ii) the number of diseases on
which the patients scored 2 or higher (moderate or more
severe comorbidity). Finally, obesity was added to the list
of comorbidities and was defined by a Body Mass Index
(body weight divided by length2), BMI ≥ 30 kg/m2.
Statistical analyses
Descriptive statistics were used to describe the presence
and severity of comorbidity and limitations in activities
and pain. Furthermore, the relation between comorbidity
and limitations in activities and pain was determined
using multivariate linear regression analyses. Dependent
variables were the WOMAC physical functioning score,
SF-36 physical functioning score, the timed walking test
and the VAS pain score. Comorbidity variables (morbidity
count and severity index) and possible confounders or
effect-modifiers (age and sex) were entered stepwise. Only
those variables that influenced both comorbidity and
functioning were added into the regression analyses as
confounders. Correlations showed that apart from age
and gender, other variables such as BMI, marital state,
education and other musculoskeletal disorders, were not
associated with comorbidity and functioning.
If significant interaction was identified (p < 0.05), strati-
fied analyses were performed. T-tests for independent
samples were performed to analyse differences in limita-
tions and pain between patients that suffered from spe-
cific diseases (all separate disease categories in the CIRS)
and those who did not suffer from these diseases. The
presence of a specific disease was defined by a score of 2
or more on the CIRS. Oneway-ANOVA was used to ana-
lyse differences in limitations in activities and pain
between patients with normal weight, overweight patients
and patients with obesity. The 11.5 version of SPSS was
used.
Results
Study population
Baseline characteristics of the study population are pre-
sented in Table 1. The majority of the patients (80%) orig-
inated from departments of Orthopaedics. The other 20%
came from departments of Rheumatology and depart-
ments of Rehabilitation.
Limitations in activities and pain
The mean score for physical functioning was 45.15 (sd =
21.62) on the SF-36 physical functioning domain (range
0–100) and 61.01 (sd = 17.76) on the WOMAC physical
functioning domain (range 0–100). The mean number of
seconds for the 10 meter timed walking test was 10.36 (sd
= 4.11). The mean pain score was 4.81 (sd = 2.56) on the
VAS.
Comorbidity
For detailed results on comorbidity, the reader is referred
to Table 2 and 3. Almost all patients (98.6%) suffered
from one or more coexistent diseases and 84.4% of the
study population suffered from one or more moderate or
severe coexistent diseases (CIRS ≥ 2). The most prevalent
conditions in this OA population were cardiac diseases
(54%), eye, ear, nose, throat and larynx diseases (96.1%),
urogenital diseases (44.4%) and endocrine and metabolic
diseases (46%).
Furthermore, the mean BMI was 27.8 (sd = 4.5). The
majority (51.7%) of the patients were overweight (BMI
between 25 and 30) and 23.6% suffered from obesity.BMC Musculoskeletal Disorders 2008, 9:95 http://www.biomedcentral.com/1471-2474/9/95
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Only 13% of the patients had no other joint complaints.
Frequently occurring other joint complaints were hand
and back problems, respectively 56.3% and 65.6%. Anal-
yses for the knee and hip OA separately revealed similar
results.
Association between comorbidity and limitations in 
activities and pain
As Table 4 shows, morbidity count was associated with
limitations in activities on the WOMAC and on the SF-36.
In older patients (age 72–84), a significant relationship
was established between morbidity count and worse per-
formance on the timed walking test. Morbidity count was
also associated with more pain measured on the VAS.
Table 4 also shows a significant relationship between
severity index and self reported limitations in activities on
the WOMAC and the SF-36. Severity index was also signif-
icantly associated with less functional performance on the
The Cumulative Illness Rating Scale (CIRS) Figure 1
The Cumulative Illness Rating Scale (CIRS).
Cardio-vascular-respiratory system 
1. Cardiac diseases (incl. hypertension) 
2. Vascular diseases 
3. Respiratory diseases 
4. Eye, ear, nose, throat and larynx diseases (incl. 
glasses) 
Gastrointestinal system 
5. Diseases of the upper gastrointestinal 
6. Diseases of the lower gastrointestinal 
7. Hepatic diseases 
Genitourinary system 
8. Renal diseases 
9. Other genitourinary diseases 
Musculo-skeletal-integumentary system 
10. Muscle, bone and skin diseases (incl. 
osteoarthritis) 
Neuropsychiatric system 
11. Neurological diseases (incl. stroke, headache 
and epileptic insults) 
12. Psychiatric diseases (incl. psychological 
counselling and sleeping disorders) 
General system 
13. Endocrine and metabolic diseases (incl. 
osteoporosis and Diabetes Mellitus) 
 
 
 
 
 
All systems are weighted from 0-4 
0 none 
1 mild - does not interfere with normal 
activity; prognosis is excellent 
2 moderate - interferes with normal 
activity; treatment is needed; prognosis 
is good 
3 severe – is disabling, treatments is 
urgently needed, prognosis is guarded  
4 extremely severe – life-threatening; 
treatment is urgent or of no avail: 
prognosis is grave 
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timed walking test. Furthermore, severity index was asso-
ciated with more pain on the VAS.
Although significant associations were found, comorbid-
ity only accounted for a small part of the variance in lim-
itations in activities and pain. R2ranged from 0.032 to
0.139 for morbidity count, from 0.058 to 0.185 for mor-
bidity count of moderate or severe diseases and from
0.056 to 0.114 for severity index.
In summary, morbidity count (having more diseases and
having more moderate or severe diseases) and severity
index were associated with more limitations in activities
and with more pain. Comorbidity, however, accounts for
only a small percentage of the variance in limitations in
activities and pain. Analyses for knee and hip OA sepa-
rately reveal similar results.
Association between the presence of specific diseases and 
limitations and pain
Because a stronger association was found for morbidity
count with CIRS score ≥ 2 than for morbidity count with
CIRS score ≥ 1 and because moderate or severe comorbid-
ity accounted for a larger part of the variance, Table 5
shows the mean differences in scores for limitations in
activities and pain between patients that suffer from mod-
erate or severe coexistent diseases (CIRS score ≥ 2) and
patients that do not. Most of the moderate or severe dis-
eases and obesity were found to be associated with limita-
tions in activities (WOMAC, SF-36 and timed walking
test) or with pain (VAS).
Discussion
The objectives of the study were (i) to describe the preva-
lence of comorbidity and (ii) to describe the relationship
between comorbidity and imitations in activities and pain
in elderly patients with knee or hip OA using a compre-
hensive inventory of comorbidity. In this study we
focussed on the cross-sectional relationship between the
presence of coexistent diseases according to the CIRS and
limitations inn activities and pain, measured by recom-
mended instruments [31], in patients with hip or knee
OA. Also, the presence of obesity was taken into account.
A study in the Netherlands showed that in a general pop-
ulation of people aged 55 years and older, the mean score
on the SF-36 ranged from 60.0 (age > 85) to 72.7 (age
55–65) [32]. So, compared to this population, the
patients in this study reported more limitations in activi-
ties (a score of 45.15 on the subscale physical functioning
of the SF-36).
Table 1: Baseline characteristics
Gender: male, n (%)  83 (28.8%)
N = 288
Age, mean (sd)  66 (8.7)
N = 287
Location of OA, n (%) 
N = 287
• knee 139 (48.4%)
• hip 72 (25.1%)
• both 76 (26.5%)
Duration of complaints (years), mean (sd)  10.1 (10.7)
N = 283
Radiological impairments in the hip *
• Normal 2 (2.2%)
• Mild 4 (4.4%)
• Moderate 13 (14.5%)
• Severe 71 (78.9%)
Radiological impairments in the knee **
• Normal 6 (4.3%)
• Mild 8 (5.8%)
• Moderate 7 (5.1%)
• Severe 117 (84.8%)
* N = 90 (from only a part of the included patients X-rays were 
available); ** N = 138 (from only a part of the included patients X-
rays were available)N, n: number; sd: standard deviation; OA: 
osteoarthritis.
Table 2: Comorbidity according to CIRS *
Mild or more severe comorbidity ** Moderate or more severe comorbidity ***
Morbidity count mean (sd) N = 288  4.32 (2.06) 2.60 (1.93)
0–12
Number of diseases n (%)
  None 4 (1.4%) 45 (15.6%)
  1 or 2 55 (19.1%) 98 (34.1%)
  3–6 144 (50%) 121 (42%)
  6–9 79 (27.4%) 22 (7.6%)
  ≥9 6 (2.1%) 2 (0.7%)
* CIRS 10 (Muscle, bone and skin diseases) was excluded from the CIRS; ** number of diseases on which patients scored ≥ 1; *** number of 
diseases on which patients scored ≥ 2/none of the patients reported a score of 4 on the CIRS;
CIRS: cumulative Illness Rating Scale; sd: standard deviation; N, n: number of patients.BMC Musculoskeletal Disorders 2008, 9:95 http://www.biomedcentral.com/1471-2474/9/95
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Almost all patients (98.6%) suffered from at least one
comorbid disease, with cardiac diseases, diseases of ear,
eye, throat and larynx, urogenital diseases and endocrine/
metabolic diseases being most prevalent. The prevalence
of comorbidity in this study population is high, compared
to earlier research. A likely explanation is that diseases
which do not interfere with normal life and which have an
excellent prognosis (CIRS score 1) also contribute to the
prevalence. For example wearing glasses or contact lenses
is seen as comorbidity since these patients score 1 on CIRS
#4. If the prevalence of comorbidity is calculated for dis-
eases that interfere with normal activity and with a poorer
prognosis (CIRS ≥ 2), then the prevalence is 84.4%. This
is still higher than reported in earlier studies on comor-
bidity in OA. A potential explanation is that in this study
a comprehensive list for comorbidity, which includes all
possible disease categories, is used. In earlier research,
limited lists of comorbidity were applied [3,15,33].
Marks, for example, used a list of five diseases: hyperten-
sion, cardiovascular diseases, peripheral vascular diseases,
diabetes and respiratory diseases [5]. It can be noted that
for example the presence of diseases of ear, eye, throat and
larynx diseases and urogenital diseases, which are most
prevalent in the present study, were not studied by Marks.
Table 4: Results from the multivariate regression analyses: association between comorbidity (morbidity count (CIRS ≥ 1), morbidity 
count (CIRS ≥ 2), severity index) and limitations in activity (WOMAC, SF-36, timed walking test) and pain (VAS) Δ*
Morbidity count  Morbidity count  Severity index
(CIRS ≥ 1) (CIRS ≥ 2)
WOMAC (physical functioning domain) -0.208‡ -0.323‡ -0.322‡
R2 = 0.056 R2 = 0.114 R2 = 0.114
SF-36 (physical functioning domain) -0.286‡ -0.350‡ -0.281‡
R2 = 0.114 R2 = 0.152 R2 = 0.113
Timed walking test
Age 50–60 ** 0.148†
Age 61–71 0.169 0.184∫
Age 72–84 0.123 0.179∫
0.262† 0.338‡
R2 = 0.139 R2 = 0.185 R2 = 0.097
VAS (pain) 0.167‡ 0.233‡ 0.230 ‡
R2 = 0.032 R2 = 0.058 R2 = 0.056
Δ Standardized β's are presented *All multivariate associations are corrected for age and gender. Other corrections were found to be unnecessary. 
** A significant interaction was found between morbidity count and age (age categories were chosen in order to have equal distribution of patients 
over the categories). ∫ 0.1 < p < 0.05; † p < 0.05; ‡ p < 0.01. WOMAC: Western Ontario and MacMaster universities osteoarthritis index; SF-36: 
MOS 36 item Short Form Health Survey; VAS: Visual Analogue Scale.
Table 3: The presence of comorbidity, measured by disease categories of the CIRS and their severity
Presence (patients that reported to have 
comorbidity (score 1, 2 or 3)) n (%)
Severity median* (25th percentile; 75th 
percentile), range
Cardiac diseases 154 (54%) 2.00 (2.00; 2.00), 0–3
Vascular diseases 73 (25.6%) 2.00 (1.00; 2.00), 0–3
Respiratory diseases 82 (28.8%) 2.00 (1.00; 2.00), 0–3
Ear, eye, throat and larynx diseases 274 (96.1%) 1.00 (1.00; 2.00), 0–3
Gastro-intestinal diseases (upper part) 99 (34.7%) 2.00 (1.00; 2.00), 0–2
Gastro-intestinal diseases (lower part) 87 (30.5%) 2.00 (1.00; 2.00), 0–3
Liver diseases 21 (7.4%) 1.00 (1.00; 2.00), 0–3
Renal diseases 32 (11.2%) 1.00 (1.00;2.00), 0–2
Urogenital diseases 126 (44.4%) 1.00 (1.00; 2.00), 0–3
Diseases of bones, joints, muscle and skin 285 (100%) 2.00 (2.00; 2.00),1–3
Neurological diseases 91 (31.9%) 2.00 (1.00; 2.00), 0–3
Psychiatric diseases 75 (26.3%) 2.00 (1.00; 2.00), 0–3
Endocrine and metabolic diseases 131 (46%) 2.00 (2.00;2.00), 0–3
N = 285; *Calculated for all patients that suffered from a specific disease. CIRS: Cumulative Ilness Rating Scale: N, n: number of patients.BMC Musculoskeletal Disorders 2008, 9:95 http://www.biomedcentral.com/1471-2474/9/95
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There were, however, studies that applied longer lists [8].
But these list were restricted, in the sense that they did not
use broad categories, but simply focussed on specific dis-
eases, for example, gallstones, prostate hypertrophy and
migraine, not taking into account all other possible dis-
eases within a category (such as other urogenital diseases
(e.g. incontinence) and other neurological diseases (e.g.
stroke)).
In the present study, evidence is provided that comorbid-
ity is negatively associated with limitations in activities
and pain. These results confirm earlier research, in which
morbidity count was associated with disability, pain and
quality of life [3,5,8]. Furthermore, this study showed that
the presence of most of the coexistent moderate or severe
diseases was related to limitations in activities and pain.
Like in this study, obesity has been found to be associated
with disability in earlier cross-sectional studies in OA
[11,17] and has been identified as a risk factor for disabil-
ity in longitudinal prognostic research [34]. Furthermore
it has been reported that obesity is an important factor in
the origin of radiological changes in osteoarthritis, either
Table 5: Limitations in activities and pain (WOMAC, SF 36, timed walking test, VAS) in patients who suffer moderate or severe 
coexistent diseases (CIRS* and obesity**) and patients who do not.
WOMAC (PF) SF 36 (PF) Timed walking test VAS (pain)
Cardiac disease
yes 31.14 40.84‡ 10.46 5.14
no 28.42 48.66 10.27 4.57
Vascular disease
yes 33.66† 36.44‡ 11.05 5.61†
no 28.77 46.98 10.21 4.66
Respiratory disease
yes 31.82 39.46† 10.44 5.14
no 29.18 46.32 10.34 4.76
Eye, ear, nose throat and larynx disease
yes 32.75‡ 40.82† 10.88 4.99
no 28.11 47.20 10.10 4.75
Disease gastro-intestinal system (upper part)
yes 34.36‡ 37.05‡ 10.65 5.15
no 28.13 47.66 10.26 4.73
Disease gastro-intestinal system (lower part)
yes 35.25‡ 35.26‡ 12.64† 5.41
no 28.48 47.13 9.91 4.71
Hepatic disease
yes 41.46† 29.26 17.16 7.50‡
no 29.40 45.43 10.21 4.77
Renal disease
yes 32.23 47.22 9.88 5.23
no 29.53 44.99 10.38 4.81
Other genito urinary disease
yes 34.61‡ 37.26‡ 12.19‡ 5.20
no 28.23 47.35 9.84 4.73
Neurological disease
yes 32.33 41.17 11.49 5.37†
no 28.84 46.30 10.02 4.66
Psychiatric disease
yes 34.20‡ 34.80‡ 11.43 5.26
no 28.58 47.55 10.11 4.73
Endocrine/metabolic disease
yes 31.94† 41.71† 11.16† 5.09
no 28.32 47.03 9.89 4.68
Body weight
Normal weight 25.38 20.41 9.84 4.43
OverweightΔ 30.78 18.65 10.25 4.87
ObesityΔΔ 31.56† 18.50† 10.74 5.04
*t-test;** one way ANOVA; † p < 0.05; ‡ P < 0.01; Δ(25 ≤ BMI < 30); ΔΔ(BMI ≥ 30) BMI: Body Mass Index; WOMAC: Western Ontario and 
MacMaster universities osteoarthritis index; SF-36: MOS 36 item Short Form Health Survey; VAS; Visual Analogue Scale; PF: physical functioning; 
CIRS: Cumulative Illness Rating Scale.BMC Musculoskeletal Disorders 2008, 9:95 http://www.biomedcentral.com/1471-2474/9/95
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by mechanical or metabolic processes [35]. Taking this
into account, the reduction of obesity and weight loss
might be an important treatment modality in OA. In a
recent study, a combination of weight loss and exercise
therapy has proven to be successful in improving self-
reported functioning. However, this study reported no
positive effect on radiological changes [36]. In the present
study, also psychiatric disease was associated with limita-
tions in activities. This finding strengthens evidence from
earlier research in OA in which psychological factors, such
as anxiety and depression, were reported to be associated
with pain and [37]. Furthermore, good mental health is
considered as a protective factor for functional decline
[34].
Some methodological issues need to be considered.
Firstly, because all patients suffered from OA and the
influence of comorbidity in an OA population was stud-
ied, CIRS category #10 was excluded from the analyses.
CIRS category #10 does not only include OA, but also
other musculoskeletal and skin diseases. Consequently,
information about those types of diseases from the CIRS
cannot be presented or included in the analyses. In an
attempt to give some information about other joint com-
plaints a question, which comprised of neck, shoulder,
hand, back, foot and other complaints, was added. Analy-
ses revealed that patients who suffer other joint com-
plaints, in particular neck complaints, report more
limitations in activities on the SF-36 and the WOMAC.
They also reported more pain on the WOMAC and the
VAS. Secondly, in this study self-reported comorbidity,
rather than comorbidity assessed by a physician, was
used. One should be aware, that self-reported comorbid-
ity could be influenced by personal or mood characteris-
tics. However, positive correlations were found between
self-reported comorbidity measures and comorbidity
from medical record reviews [38]. Thirdly, of the 775
patients who were initially contacted, 364 patients volun-
teered to participate and 288 patients were included in the
study. Non-response analyses showed that there were no
differences in age and gender between the patients who
were contacted and the patients who were finally included
in our study. Some differences were found in location of
OA. But since, results of the study did not differ between
patients with hip OA and patients with knee OA, non-
response was not expected to influence the results.
Fourthly, one can debate whether all diseases have the
same impact on functioning and result in the same bur-
den. The comparability of equal scores on CIRS might
provide a problem in assessing the influence of comorbid-
ity. Fifthly, results were only corrected for age and gender
and not for other variables such as BMI, marital status,
education and other musculoskeletal disorders, since cor-
relations showed that these variables were not correlated
with comorbidity and functioning. These variables, there-
fore, were not considered as confounders. Lastly, the
influence of the disease on daily activities is part of the
definition of severity (see figure 1). Some of the variance
in the relationship between severity and functional prob-
lems can be attributed to the definition of severity in the
CIRS. Scoring severity on the CIRS is determined by both
interference with normal life and medical issues, such as
prognosis and treatment. Separating those two aspects in
scoring severity of comorbidity seems advisable. In all, in
spite of its metric flaws, until now no better, comprehen-
sive instrument on comorbidity is available.
Conclusion
Patients included in this study were recruited from hospi-
tals and rehabilitation centers. Results are important for
this specific group of patients, since it is expected that with
the aging of the population an increasing number of eld-
erly people with osteoarthritis will need rehabilitation.
The prevalence of comorbidity in this population of eld-
erly patients with hip or knee OA was high and an associ-
ation between comorbidity and limitations and pain was
established. Comorbidity, however, accounted for only a
small percentage of the variance and can therefore not be
considered as the only important aspect in an elderly pop-
ulation that may contribute to limitations in activities and
pain. Other aspects related to aging, such as physical
impairments (radiological changes, muscle strength and
range of motion) and cognitive impairments, but also
social network and psychosocial variables, are expected to
play an important role in limitations in activities and pain
in elderly patients with hip or knee OA. More scientific
knowledge of the impact of those factors is needed and
further research should elaborate on these aspects.
The results of this study emphasize the importance of
comorbidity in the rehabilitation of elderly patients with
osteoarthritis of the hip or knee. Clinical practitioners
should be aware of the relationship of comorbidity with
functional problems in OA patients.
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